Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Interferon Sciences |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002012 |
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic HIV+, AIDS-related complex (ARC) patients.
Condition | Intervention |
---|---|
HIV Infections |
Drug: Interferon alfa-n3 |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind |
Official Title: | Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 45 days of study entry:
Study ID Numbers: | 069A, 90-151ME |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002012 |
Health Authority: | United States: Food and Drug Administration |
Acquired Immunodeficiency Syndrome AIDS-Related Complex Interferon Type I, Recombinant |
Interferon-alpha Virus Diseases Interferon Type I, Recombinant Sexually Transmitted Diseases, Viral HIV Infections Interferons |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome AIDS-Related Complex Interferon Alfa-2a Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections Slow Virus Diseases Immune System Diseases Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs |
Infection Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Therapeutic Uses Lentivirus Infections Growth Inhibitors Angiogenesis Modulating Agents |